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Abstract: Replacement of the congenitally deficient factor VIII or IX through plasma-derived 
or recombinant concentrates is the mainstay of treatment for hemophilia. Concentrate infusions 
when hemorrhages occur typically in joint and muscles (on-demand treatment) is able to resolve 
bleeding, but does not prevent the progressive joint deterioration leading to crippling hemophilic 
arthropathy. Therefore, primary prophylaxis, ie, regular infusion of concentrates started after the first 
joint bleed and/or before the age of two years, is now recognized as first-line treatment in children 
with severe hemophilia. Secondary prophylaxis, whenever started, aims to avoid (or delay) the pro-
gression of arthropathy and improve patient quality of life. Interestingly, recent data suggest a role 
for early prophylaxis also in preventing development of inhibitors, the most serious complication 
of treatment in hemophilia, in which multiple genetic and environmental factors may be involved. 
Treatment of bleeds in patients with inhibitors requires bypassing agents (activated prothrombin 
complex concentrates, recombinant factor VIIa). However, eradication of inhibitors by induction 
of immune tolerance should be the first choice for patients with recent onset inhibitors. The wide 
availability of safe factor concentrates and programs for comprehensive care has now resulted in 
highly satisfactory treatment of hemophilia patients in developed countries. Unfortunately, this is 
not true for more than two-thirds of persons with hemophilia, who live in developing countries.
Keywords: bleeding, comprehensive care, clotting factor concentrates, hemophilia, inhibitors, 
prophylaxis, treatment
Introduction
Hemophilia A and B are congenital bleeding disorders caused by a deficiency or 
  complete absence of coagulation factor VIII (FVIII) or factor IX (FIX), respectively. 
These X-linked disorders represent the large majority of inherited deficiencies of   clotting 
factors, occurring in approximately one per 5000 and one per 50,000 male births, with no 
racial predilection.1 According to their residual endogenous FVIII/FIX   concentrations, 
individuals with a factor level ,1 IU/dL are classified as severe   hemophiliacs and 
represent about half of diagnosed cases. Subjects with   factor levels between 1–5 IU/dL 
and .5 IU/dL have moderate and mild hemophilia,   respectively. Although the bleeding 
phenotype may be rather heterogeneous, even in severe hemophiliacs,2 this classification 
reflects the severity of clinical symptoms, with spontaneous joint and muscle bleeds 
being largely confined to patients with severe hemophilia.
Hemophilia A and B are difficult to distinguish from a clinical point of view. 
Replacement of hemostatic concentrations of the deficient factor is the mainstay of 
treatment for bleeding episodes, according to the type and severity of bleeds and until 
complete resolution of symptoms (Table 1).3 Recurrent joint bleeds, inevitably leading Journal of Blood Medicine  2010:1 submit your manuscript | www.dovepress.com
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to crippling arthropathy,4 were the hallmark of this disease 
before the 1970s, when plasma fractions containing FVIII or 
FIX were still not available. At that time, mortality for bleeding 
was very high, and the life expectancy of persons with hemo-
philia was much lower than that of the general population.5,6 
The discovery of cryoprecipitate in 1964 and the subsequent 
development of lyophilized factor concentrates in the 1970s 
paved the way for modern, effective hemophilia replacement 
therapy, providing the possibility of home   therapy and enabling 
severe hemophiliacs to treat joint bleeds as early as possible. 
This was associated with a significant reduction in morbidity 
and the prospect of a more normal lifestyle for patients and 
their families.5 Subsequent to widespread blood-borne virus 
transmission in the late 1970s and early 1980s caused by the   
use of pooled plasma in the   manufacture of   factor concentrates, 
the need for improved safety of treatment became crucial for 
the   hemophilia community. As a result, viral inactivation tech-
niques for the production of   plasma-derived factor concentrates 
were implemented. However, the most important advance 
was recombinant gene technology and protein purification 
techniques, which enabled the development of highly purified 
recombinant FVIII (rFVIII) and FIX products.5,7 The viral 
safety of factor concentrates dramatically improved the treat-
ment and quality of life of hemophilia patients and significantly 
contributed to the increased use of regimens of regular infu-
sion of factor concentrates to prevent bleeding and resulting 
joint damage (  primary   prophylaxis) and of home treatment. 
Thus, with viral safety now less of an issue and with the more 
  widespread use of prophylaxis to prevent arthropathy, the most 
serious and challenging complication of treatment, mainly in 
hemophilia A, there remains the risk of developing inhibitory 
alloantibodies.5,8
Patients with hemophilia may now receive excellent 
treatment, based on very safe antihemophilic products and 
effective approaches for comprehensive care, and achieve an 
excellent quality of life. Unfortunately, this is true only for 
patients living in developed countries, in which a wide variety 
of factor concentrates are available, as shown in Table 2. 
The aim of this review is to address current advances and 
  clinical strategies for treatment of hemophilia, also focusing 
on ongoing issues and perspectives in this setting.
Table 1 Hemostatic factor concentrate dosages for replacement 
treatment in hemophilia
Setting* FVIII (IU/kg)** FIX (IU/kg)**
Mild/moderate joint or muscle bleed 20–30 20–40
Severe joint or muscle bleed,  
mucosal bleeding with anemia, 
moderate post-traumatic bleed 
30–50 40–60
CNS bleeding, cranial trauma,  
surgery prophylaxis
50–100 50–100
Notes: *Treatment should be administered until complete resolution of bleeding or 
wound healing in the case of surgery. **Administration of 1 iU/kg of factor concentrate 
is assumed to result in an approximately 2% increase of Fviii and a 1% increase of FiX 
levels. According to their half-life in the absence of inhibitory antibodies, Fviii and FiX 
concentrates are usually given every 12 and 24 hours, respectively.
Abbreviations: CNS, central nervous system; Fviii, factor viii; FiX, factor iX.
Table 2 Type of products currently used for replacement therapy in hemophilia A and B
Type of product Comments
Hemophilia A
intermediate-purity plasma-derived Fviii concentrates  Purification from cryoprecipitate through multiple precipitation;  
single-step viral inactivation 
High-purity plasma-derived Fviii concentrates Purification through ion-exchange, heparin ligand or monoclonal  
antibody chromatography; single- or double-step viral inactivation 
Full-length recombinant Fviii concentrates –   From BHK-cultured cells in the presence of HSA, stabilized  
in sucrose; SD viral inactivation
–   From CHO-cultured cells without HSA, stabilized in 
trehalose; SD viral inactivation
B-domain deleted recombinant Fviii 
concentrate
From CHO-cultured cells without HSA and animal protein;  
SD viral inactivation and nanofiltration 
Hemophilia B
High-purity plasma-derived FiX concentrates Purification through immunoaffinity or ion exchange plus carbohydrate-  
or heparin-ligand chromatography; single- or double-step viral inactivation
Recombinant FiX concentrate From CHO-cultured cells, without HSA; nanofiltration 
Hemophilia with inhibitors (by-passing agents)
APCC Plasma-derived; batch-controlled surface activation  
of prothrombin complex; vapour heat viral inactivation
rFviia From BHK cultured cell; Fvii autoactivation during 
chromatographic purification; SD viral inactivation 
Abbreviations: BHK, baby hamster kidney; CHO, chinese hamster ovary; HSA, human serum albumin; SD, solvent/detergent; Fviii, factor viii; FiX, factor iX; APCC, 
activated prothrombin complex concentrates; rFviia, recombinant activated factor vii.Journal of Blood Medicine  2010:1 submit your manuscript | www.dovepress.com
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Prophylaxis versus on-demand 
replacement therapy
If hemophilia is already known to be in the family, the 
  disorder is usually diagnosed before the occurrence of signifi-
cant bleeding, ie, in the neonatal period or earlier by prenatal 
diagnostic methods.9 In sporadic cases (first diagnosis in a 
family, approximately 30%–40% of cases), the severe patients 
are diagnosed before the age of one year because of mucosal 
or soft tissue hemorrhages,   usually after   trauma.10 However, 
an incidence of intracranial or   extracranial   hemorrhage at 
delivery of 3.6% has been   calculated.11 With the exception of 
these and of patients requiring surgery, replacement treatment 
in hemophilic children is usually started at the time of the first 
joint bleed, occurring in most patients before the age of two 
years, together with joint mobilization and load.2 Ankles, and 
later knees and elbows, are most frequently affected. How-
ever, on-demand factor infusion, which is the treatment in 
response to an acute bleeding episode, is able to stop the hem-
orrhage, but does not impact the presence of blood already 
accumulated in the affected joint and its deleterious effects 
on synovial tissues.4   Deposition of iron is believed to trigger 
an inflammatory reaction, release of oxidative products, and 
vascular   proliferation.4 Synovial hyperemia and hypertrophy 
facilitates repeated bleeding episodes (“target joint”) and 
amplification of phenomena leading, in a vicious cycle, to 
chronic arthritis, with progressive damage of cartilage and 
bone. Degenerative joint disease (hemophilic arthropathy) 
results in decreased range of motion, functional impairment, 
and chronic pain. This is associated with reduction of   physical 
fitness and muscle   atrophy, and in turn, exacerbation of 
  functional joint   impairment and tendency to bleeding.
Although individual patterns of bleeding vary   substantially, 
even in patients with severe FVIII/FIX deficiencies,2,12 most 
patients experience 10–15 joint bleeds per year.13 Clinical 
and radiologic follow-up of children with severe hemo-
philia has shown that progressive joint degeneration can 
be   documented in more than half of patients within six 
years from the first bleeding episode, often associated with 
restriction of activity.13 The severity of joint disease and 
dysfunction is closely related to the frequency of bleeding 
episodes, given that a direct relationship between the clinical 
or radiologic scores describing the severity of arthropathy14,15 
and the cumulative number of hemarthroses has been clearly 
shown.13,16
The recognition that patients with moderate or mild 
hemophilia (who have FVIII/FIX levels .1%) show a low 
frequency of joint bleeds and rarely develop severe arthropa-
thy17 led to definition of the pathophysiologic background 
and pioneer prophylaxis regimens in Sweden. The aim of 
treatment was (and still is) to minimize the number of joint 
bleeds from an early age by converting the severe form of 
hemophilia to a milder form, in order to prevent or reduce 
musculoskeletal impairment from hemophilic arthropathy. 
Prophylaxis in hemophilia is defined as the infusion of factor 
replacement concentrates in order to prevent bleeding, and 
usually refers to a regular, continuous long-term regimen of 
treatment, as shown in Table 3. The results of the Swedish18,19 
and of subsequent, retrospective, uncontrolled studies16,20–23 
documented the clinical and social benefits of different 
prophylaxis regimens, in terms of reduction of frequency 
of total and joint bleeds and, in particular, on long-term 
clinical outcome in terms of arthropathy, assessed by clini-
cal and radiologic scores, and of patient quality of life, as 
reported in Table 4. These studies also showed that the ear-
lier the start of prophylaxis, the better the results for patient 
joint status. These findings led to the current definitions of 
prophylaxis,24,25 which is focused on the prevention of joint 
abnormalities, in order to enable normal life and psychosocial 
development for hemophilic children, including the possi-
bility of physical activities, regular school attendance and, 
consequently, social and work opportunities. Even though the 
number of joint bleeds resulting in   irreversible joint damage 
Table 3 Definitions of replacement treatment regimens in hemophilia
Regimen Definition
Primary prophylaxis A Long-term continuous* treatment started after the first joint bleed  
and before the age of two years
Primary prophylaxis B Long-term continuous* treatment started before the age of two years,  
in the absence of clinically evident joint bleeds
Secondary prophylaxis A Long-term continuous* treatment not fulfilling the criteria for primary  
prophylaxis, ie, started after two or more joint bleeds or at age . two years
Secondary prophylaxis B (short-term prophylaxis) intermittent regular (short-term) treatment, generally started  
because of frequent bleeds 
On-demand or episodic therapy Treatment given when bleeding occurs
Note: *At least 46 weeks/year, with the aim of treating 52 weeks/year up to adulthood.Journal of Blood Medicine  2010:1 submit your manuscript | www.dovepress.com
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is still unknown,4 recent revisions by the European Pediatric 
Network for Haemophilia Management group25 now define 
primary prophylaxis as regular long-term regimens started 
before the age of two years, after the first joint bleed (A), or 
in the absence of clinically evident joint bleeds (B). Treat-
ment started after the age of two years or after two or more 
joint bleeds is considered to be secondary prophylaxis, and 
is aimed at avoiding (or delaying) the progression of joint 
damage.25,26
The lack of randomized controlled trials comparing 
prophylaxis versus on-demand treatment in hemophilic 
children was highlighted by a Cochrane review in 2005.27 
Recently two studies carried out with rFVIII products 
addressed this issue. The Joint Outcome Study (JOS) was 
the first published, prospective, randomized trial comparing 
prophylaxis versus on-demand treatment.28 The primary 
endpoint of the study was the prevention of joint dete-
rioration by prophylaxis, started prior to or at the time of 
the second joint bleed (between six and 30 months), and 
assessed at the age of six years by radiography and/or by the 
most advanced approach for evaluating joint structure, ie, 
magnetic resonance imaging (MRI).29 Beyond the expected 
impact on number of bleeds, including life-threatening 
hemorrhages, the JOS study provided evidence of an 
approximately six-fold reduction of risk of joint damage 
in 32 children on prophylaxis with rFVIII 25 IU/kg every 
other day compared with 33 patients receiving intensive 
on-demand treatment (40 IU/kg, then 20 IU/kg at 24 and 
72 hours and every other day until recovery). Interestingly, 
only the MRI assessment showed a significant difference in 
joint outcome, with more than half the joint abnormalities 
being not detectable by conventional radiologic evalu-
ation.28 The JOS study confirmed that MRI is the preferable 
imaging technique in hemophilic children, also being able 
to reveal signs of joint deterioration in the absence of overt 
history of hemarthroses and of abnormalities at physical 
examination, although the interpretation and scoring of 
findings is still debated.29 Based on the results of the JOS 
study showing the efficacy of prophylaxis in preserving 
joint health and preventing life-threatening hemorrhages, 
the authors concluded that prophylaxis in hemophilic 
children is justified.
The results of another randomized trial carried out in 
Italy, the ESPRIT (Evaluation Study on Prophylaxis: a 
Randomized Italian Trial), have been recently published 
in abstract form.30 Forty patients aged younger than seven 
years (median two years) with negative clinical and radio-
logic scores at study entry were randomized to receive 
rFVIII 25 IU/kg three times weekly or on-demand treatment 
($25 IU/kg until complete healing). Significantly lower 
bleeding frequency and Petterson scores have been reported 
in children on prophylaxis than in those on on-demand treat-
ment after a long-term follow-up of 10 years. The results of 
the JOS and ESPRIT studies definitely provided evidence-
based recommendations for prophylaxis as the treatment of 
choice in hemophilic children, as recommended by the World 
Health Organization (WHO) and the World Federation of 
Hemophilia since 1994.31
Although there is general agreement among investiga-
tors that early initiation of prophylaxis (usually before two 
years of age) is ideal, there is still debate about the intensity 
of treatment regimens32 and how to initiate prophylaxis, as 
shown in Table 5. In this respect, barriers to early imple-
mentation of prophylaxis are the need for frequent venous 
access and adequate training of families for home treatment, 
in order to maximize adherence to such a highly demanding 
treatment, the perceived need for which and knowledge of 
benefits are often poor.33 These problems and the differences 
in patient bleeding patterns (approximately 10% of severe 
hemophiliacs are mild bleeders and variability in the age of 
Table 4 Documented clinical benefits and barriers to implementation of prophylaxis in children with hemophilia
Clinical advantages Barriers
•   Reduction of severity (prevention of life-threatening  
hemorrhages) and of frequency of total and joint bleeds
•   Costs of coagulation factor concentrates  
(prohibitive in developing countries)
•   Prevention/reduction of joint and muscle impairment  
(hemophilic arthropathy) → reduction of physical restrictions  
and ability to participate in physical activities and sports
•   inadequate peripheral venous access in children 
(need for central venous access devices, more 
recently arteriovenous fistulae)
•   Reduction of hospitalizations, professional visits  
and examinations
•   Reduction of patients’/caregivers’ school/work days lost → regular school  
attendance and better achievement → better work and social opportunities
•   Acceptance of treatment (poor perceived need  
and knowledge of benefits, heterogeneity  
of bleeding phenotype)
• Home treatment not possible
•   Reduction of psychologic impairment and higher levels of quality of life
•   Prevention of development of inhibitors (to be further evaluated)
•   Logistic problems (difficult access  
to hemophilia treatment centers)Journal of Blood Medicine  2010:1 submit your manuscript | www.dovepress.com
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first joint bleed has been reported)2,12 led to individualization 
in   implemention of full-dose primary prophylaxis after an 
early start of treatment using step-up regimens. While the 
Swedish approach   encompasses a brief temporary once-a-
week infusion step, with the aim to escalate children quickly 
towards twice-weekly infusions and then to three infusions 
per week as full prophylaxis, based on the availability of 
adequate peripheral veins or, more rarely, on the   bleeding fre-
quency,34 the Canadian approach consists of a more gradual 
escalation based on the number of joint bleeds,   comprising 
once-weekly infusions at a dose of 50 IU/kg started between 
one and two years of age, with a clinical follow-up every three 
months. Patients experiencing three bleeds in the same joint 
or four total bleeds over a three-month period then have an 
increase in their prophylaxis dose by infusion of 30 IU/kg 
twice weekly and then by a regimen of 25 IU/kg every other 
day.35 Interestingly, in the Canadian experience, 40% of chil-
dren maintained the once-weekly infusion and 16% reached 
the full-dose prophylaxis regimen over a median 4.1-year 
follow-up. However, long-term follow-up studies of patients 
treated with such regimens are needed to evaluate the possible 
impact on joint outcome (the development of target joints in 
22.5% of children has raised some concerns).35   Nevertheless, 
the gradual, escalating   introduction of prophylaxis allows 
patients and families to accept peripheral venipunctures better 
psychologically, enables development of robust veins capable 
of being   punctured more frequently, achieves independence 
for home treatment. Both the Swedish and Canadian experi-
ences resulted in a significantly diminished need for central 
venous access devices (CVADs).
A major  barrier to the widespread use of prophylaxis in 
hemophilic children, as shown in Table 4, remains the costs of 
clotting factor concentrates, which are particularly   prohibitive 
in developing countries.33 The JOS study showed clearly 
that factor consumption for patients on regular   prophylaxis 
is about 2.5-fold higher than that of episodic treatment. The 
annual cost of prophylaxis for a child weighing 50 kg was 
estimated to amount to $300,000.28 However, on-demand 
treatment is still the predominant replacement approach in 
many developed countries. According to recent data, only 
19% of children receive primary prophylaxis in the US, and 
a large variability is reported also in European countries, with 
highest figures (73%) in Sweden.36 In this respect, the wider 
availability of safer rFVIII products was the determinant for 
large-scale implementation of primary prophylaxis in the 
1990s in many countries outside Northern Europe.7
Finally, there are some other ongoing issues with regard 
to the duration of primary prophylaxis and delayed start of 
prophylaxis. Recent recommendations state that prophylaxis 
should be continued indefinitely, and that it is the treatment 
of choice for hemophiliacs at any age.37–39 Some groups of 
investigators have tried to evaluate variables affecting the 
phenotypic severity of the disease in order to identify those 
patients able to stop prophylactic treatment without adverse 
clinical effects.40,41 Fischer et al40 reported that about   one-third 
of patients who discontinued prophylaxis permanently 
  maintained a low number of joint bleeds. Similar findings 
were shown in a Dutch-Danish study.41 Thus, in order to 
predict which patients might be able to stop prophylaxis 
safely, a score based on age at start of prophylaxis, weekly 
dose of prophylaxis, and joint bleed frequency on prophylaxis 
has been proposed.41 However, more research is required 
to identify these patients and to determine whether discon-
tinuing prophylaxis during adolescence or adulthood may 
compromise the positive joint outcome achieved.
As previously mentioned, due to the fact that in many 
countries primary prophylaxis was introduced more recently 
on a large scale, secondary prophylaxis has been started in 
many children of school age or later, in most cases because of 
a high bleeding frequency or after the development of target 
joints when patients were treated on-demand. There are a 
number of studies in the literature on the role of   secondary 
prophylaxis in children,13,42–45 and more recently also for 
adult patients.46–48 On the whole, these studies show that 
Table 5 Prophylaxis regimens in hemophilia
High-dose regimens (Sweden, Germany, UK, US, Italy)
Hemophilia A 25–40 iU/kg three times weekly or every other day
  escalating dose regimens 500 iU once weekly, rapidly increased to twice and three times 
weekly on the basis of venous access (Sweden)
50 iU/kg once weekly → 30 iU/kg twice weekly → 30 iU/kg 
every other day, according to bleeding frequency (Canada)
Hemophilia B 25–40 iU/kg two or three times
Intermediate-dose regimens (The Netherlands)
Hemophilia A 15–25 iU/kg two to three times weekly
Hemophilia B 30–50 iU/kg once to twice weeklyJournal of Blood Medicine  2010:1 submit your manuscript | www.dovepress.com
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even delayed prophylaxis is able to reduce the frequency 
of   bleeding as well as patients’ physical and psychologic 
  restrictions. There are, however, uncertainties regarding the 
possible impact on the progression of arthropathy, particularly 
in adults. However, the improvement of quality of life appears 
to counterbalance the undoubtedly higher costs of secondary 
prophylaxis, also in adolescent and adult patients.49
Prophylaxis, type of concentrate, 
and development of inhibitors
Approximately 30% of patients with severe hemophilia A gen-
erate antibodies (inhibitors) against therapeutically adminis-
tered FVIII, typically during the first 20–50 days of exposure.50 
These figures are lower in severe hemophilia B patients (about 
5%), although inhibitor prevalence is similar to that reported 
in hemophilia A in some populations.   According to the highest 
documented inhibitor level and the presence of an anamnestic 
peak at factor concentrate re-exposure, high-responding (.5 
BU/mL) or low-responding (always ,5 BU/mL) inhibitors 
are distinguished. In a minority of patients, inhibitors are 
detected temporarily, and are no longer found during factor 
replacement treatment (transient inhibitors).
Development of inhibitors remains the most serious and 
challenging complication of treatment for hemophilia, because 
the safe and effective standard of care, particularly prophylaxis, 
is precluded. Despite improvements in   strategies for treatment 
in this setting,51,52 patients with inhibitors experience higher 
levels of morbidity and mortality53,54 and a poorer quality of 
life related to their orthopedic status than patients who do not 
develop inhibitors.54,55 Moreover, the economic burden of this 
complication is the highest reported for a chronic disease.54
Inhibitors develop as a result of a complex   interplay 
between many genetic and environmental factors (Figure 1).56 
The role of the type of causative mutations in FVIII or 
FIX genes has been clearly recognized and is the basis for 
increased risk in patients with a family history of   inhibitors.57 
Concordance family studies show that   factors other than 
FVIII/FIX gene mutations are involved. As a consequence of 
the higher   clinical impact of inhibitors, most studies   have been 
carried out in patients with hemophilia A. There is an emerg-
ing role for polymorphisms of immunoregulatory genes that 
may increase (  interleukin-10 and tumour necrosis factor-α) 
or reduce (CTLA-4) inhibitor risk, the   heterogeneous ethnic 
  distribution of which may correlate with the higher inhibitor 
risk in non-Caucasian patients.58–60 The role of nongenetic 
factors has been increasingly   supported by   evolving concepts 
of the immune response based on the “danger model”.61 The 
immune system is activated by alarm signals from injured 
tissues to a greater extent than by recognition of nonself. 
In this respect, the presentation of exogenous FVIII/FIX 
may not be sufficient for initiating an immune response. 
In the presence of dangerous conditions (ie, severe bleeds, 
or trauma or surgery with major tissue injury), the foreign 
protein is intensively presented (high-dose and/or prolonged 
treatment) in association with signals that upregulate the 
cellular T- and B-lymphocyte response. Conversely, regular 
exposure to lower doses of antigen, in the absence of danger 
signals, which occurs with regular prophylaxis, may allow 
the immune system to tolerate the foreign protein. Recent 
studies62,63 consistently report an increased inhibitor risk 
for patients receiving   initial intensive treatments (surgery 
or severe bleeds requiring high-dose and/or prolonged 
  treatment). On the other hand, after preliminary uncontrolled 
data were published,22,64 a protective effect against the devel-
opment of inhibitors has been shown by multivariate analysis 
in a case-control Italian study,65 reporting a 70% reduction of 
inhibitor risk in children starting prophylaxis at a median age 
of 35 months compared with children receiving on-demand 
treatment. Similar   findings were reported in the larger mul-
tinational Concerted Action on Neutralizing Antibodies in 
Severe Hemophilia A (CANAL) study, in which early regu-
lar prophylaxis (started at a median age of 20 months) was 
an independent predictor associated with a 60% lower risk 
FVIII/FIX gene mutations
large deletions, translocations
nonsense mutations
Immune response genes
IL-10, TNFα, CTLA-4,
MHC class I/II, others?
Treatment-related
factors
type of product?
prophylaxis
continuous infusion?
intensive treatment
Immune system
challenges
tissue damage
(severe bleeds, 
surgery)
vaccinations,
infections? 
GENETIC BACKGROUND
INHIBITOR DEVELOPMENT
ENVIRONMENTAL FACTORS
Figure 1 Factors contributing to inhibitor development in hemophilic patients. 
Multiple genetic and environmental factors interact during the first exposures to 
factor concentrate replacement treatment. Most data have been obtained from 
studies in hemophilia A patients, who develop inhibitors with higher frequency than 
those with hemophilia B.Journal of Blood Medicine  2010:1 submit your manuscript | www.dovepress.com
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of development of inhibitors than on-demand treatment.62 
Starting with these pathophysiologic and clinical observa-
tions, inhibitor prevention strategies avoiding immunologic 
danger signals are being investigated. A German experience 
has recently been published.66 A “tolerization” regimen of 
25 IU/kg FVIII once weekly was started early, as soon as a 
bleeding tendency was shown in soft tissues and muscles (at 
approximately 10 months of age). The frequency of infusion 
was increased to two or three times a week as required accord-
ing to the   bleeding tendency. Moreover,   danger signals were 
minimized by avoidance of FVIII   infusions during infections, 
on the same day as vaccinations, and delaying elective surgery 
during the first 20 days of exposure. Only one of 14 patients 
receiving this new regimen developed inhibitors compared 
with 14 of 30 retrospectively analyzed children treated with 
standard prophylaxis, resulting in a .90% reduction of risk.66 
  Therefore, at least in hemophilia A, clinical approaches at the 
start of replacement treatment are expected to evolve towards 
prophylaxis regimens able to prevent development of inhibi-
tors together with joint deterioration. The encouraging data 
for additional benefits of primary prophylaxis could further 
help to overcome barriers to the acceptance of this type of 
regimen that has undeniably transformed the lives of children 
with severe hemophilia and their families.49
The CANAL study also investigated the relationship 
between FVIII product type (ie, plasma-derived versus 
recombinant) and switching between FVIII products with 
regard to the risk of inhibitor development.67 Plasma-derived 
FVIII products were not associated with a lower risk of inhibi-
tors than rFVIII products, nor did switching between FVIII 
product brands increase the risk of inhibitors.67 At variance 
with the comparison of the retrospective French cohorts 
showing lower inhibitor risk in patients treated with a plasma-
derived product,68 the CANAL results were consistent with 
the findings of another recent English study which failed to 
detect significant differences in inhibitor risk by multivariate 
analysis,69 and highlighted that clinically relevant inhibitors 
develop with substantially comparable figures irrespective of 
type of product. On the other hand, the prospective long-term 
rFVIII registration studies clearly showed that about one-third 
of detected inhibitors were transient and that less than half 
were   high-responding inhibitors (.10 BU/mL).70 Therefore, 
possible discrepancies in inhibitor detection are likely to be 
due to the different study designs (retrospective, multicenter, 
and multinational, involving many product brands and 
modalities of   treatment, with different exposure days) and, 
notably, to the fact that low-titer and transient inhibitors are 
usually missed in the older plasma-derived FVIII studies, thus 
  resulting in   underestimation of overall inhibitor incidence. On 
the whole, the hypothesized protective role of von Willebrand 
factor contained in plasma-derived concentrates in terms 
of   reducing FVIII immunogenicity is presently supported 
more by in vitro data and preclinical experiments in animal 
models71 rather than by clinical data.
Management of inhibitors  
in hemophilia
Strategies for clinical management of patients with   inhibitors 
are rather heterogeneous because of the variability of clinical 
manifestations and of responsiveness to available therapies 
and, in particular, the lack of rigorous studies   providing 
enough high-level evidence to formulate   treatment guide-
lines. The development of a specific inhibitor to FVIII or 
FIX results in partial or complete lack of efficacy of factor 
concentrates. In patients with transient or   low-responding 
inhibitors, or with an actual low inhibitor titer (,5 BU/
mL), bleeding episodes may be managed by increased dos-
ages of FVIII/FIX concentrates. However, in the majority 
of patients with   high-responding inhibitors, bypassing 
agents (eg,   recombinant activated factor VII, rFVIIa, and 
activated prothrombin complex concentrates, aPCC) are 
needed (Figure 2) and   different regimens of treatment (dose, 
  modality and frequency of administration) are reported.51,72,73 
  Moreover, recent anecdotal reports suggest improved   efficacy 
with combined sequential use of rFVIIa and aPCC, and 
increasing data are being   collected on prophylactic regimens 
with both agents for patients with life-threatening or very 
  frequent bleeding.52,73 Given the serious clinical   consequences 
of inhibitors, immune   tolerance   induction (ITI) by means 
of frequent and long-term administration of concentrates to 
Transient or
low-responding  
 
High-responding 
Immune
tolerance
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INHIBITOR
By-passing
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on demand
prophylaxis?
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Figure 2 Current treatment strategies for patients with hemophilia who develop 
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eradicate inhibitors and restore standard factor concentrate 
treatment and prophylaxis feasibility (Figure 2), is attempted 
in most patients as soon as possible after diagnosis of 
  inhibitors, especially in children.72–76 As for risk factors of 
inhibitor development, the majority of studies have also been 
carried out in patients with hemophilia A, using a variety 
of therapeutic protocols (ie, dose and type of concentrate, 
interval of infusions, and immunomodulating agents).76–80 
Data for hemophilia B are even more scarce because ITI is 
rarely attempted in these patients, with severe anaphylactic 
reactions and development of nephrotic syndrome having 
been reported.77
In the 1990s, retrospective data for a considerable 
  number of patients who underwent ITI were collected in 
order to obtain more information about prognostic of ITI 
success. Most of the data comes from three registries, ie, 
the International Immune   Tolerance Registry (IITR),78 the 
North American Immune Tolerance Registry (NAITR),79 
and the German Immune Tolerance Registry,80 with success 
rates reported between 60% and 80%. In a   meta-analysis of 
the data from the IITR and the NAITR, published in 1999, 
among the variables analyzed (ie,   historical inhibitor peak 
titer, inhibitor titer before ITI initiation, FVIII dosing, and 
FVIII products), only a historical inhibitor peak titer ,50 BU 
and an inhibitor titer ,10 BU immediately before ITI initia-
tion were identified as predictors of ITI   success.81 However, 
ITI registries  had some   limitations, ie, a   retrospective design 
and   heterogeneous patient and treatment characteristics, in 
particular the definition of endpoints. Recently, an Italian 
retrospective-prospective registry providing central revision 
of ITI outcome showed that, similar to inhibitor development, 
the type of FVIII gene mutations may predict ITI success.82 
However, the optimal ITI regimen is still being debated. The 
International Immune Tolerance Induction Study, the first 
prospective, randomized, controlled trial of ITI in good-
risk patients, focusing on the dose issue (200 IU/kg/day 
versus 50 IU/kg t.i.w.),83 and the Rescue Immune Tolerance 
(RESIST study), addressing the role of different types of 
FVIII concentrate in ITI rescue and now in its early phase,84 
are expected to resolve some of the unanswered questions. 
With the aim of providing useful information for hemophilia 
caregivers, an international panel of opinion leaders devel-
oped consensus recommendations for ITI on the basis of 
the available published literature and the collective clinical 
experience of the panel.76 Rated   according to the level of 
supporting evidence, the main consensus recommendations 
for the FVIII product type were that ITI is successful using 
FVIII products   regardless of von   Willebrand factor content, 
with no definitive data supporting the superiority of any 
FVIII product, and that most patients can effectively achieve 
tolerance with the same FVIII product in use at the time of 
inhibitor detection. For all these   recommendations the level 
of evidence was IIb.76
Venous access is a crucial issue in the management of 
children undergoing ITI, as well as in those on primary pro-
phylaxis. Although peripheral venipuncture is the first choice, 
CVADs are often necessary for these young children, espe-
cially for high-dose regimens. Totally implantable catheters 
(ports) are preferred to external CVADs because of the lower 
risk of complications, especially infection and thrombosis. 
However, CVADs should not be used routinely in children 
and, if required, should be removed as soon as feasible.85,86 
Indeed, the development of catheter infections may cause 
dangerous interruptions to prophylaxis, and in particular to 
ITI. This may prolong time taken to achieve successful toler-
ance or lead to treatment failure by provoking an anamnestic 
increase in the inhibitor titer.76 Arteriovenous fistulae could be 
considered a promising option for children aged one year and 
older who have experienced CVAD failure. Indeed, positive 
results have been reported in two studies conducted in Italy 
and the US, respectively.87,88 However, this approach requires 
a highly experienced surgeon and continuous follow-up, so 
should be performed only in specialized centers.
Comprehensive care  
of hemophilic patients
Hemophilia care does not consist only of replacement therapy 
and hematologic follow-up. The hematologist’s clinical and 
laboratory expertise should be conjugated to other diagnostic 
and therapeutic facilities for the management of bleeding at 
various sites, surgery, and chronic complications. The need 
for a multidisciplinary integrated approach at specialized 
centers for this rare congenital disease requiring complex 
management has been recognized since the 1960s.89,90
Comprehensive care of hemophilic patients addresses 
treatment and prevention of bleeding, long-term   management 
of hemophilic arthropathy and other complications of bleed-
ing, management of significant complications of treatment 
(development of inhibitors and transfusion-  transmitted infec-
tions), and the psychosocial support and education required 
to manage the bleeding disorder, i  ncluding venous access 
and home treatment. Therefore, the core team at a hemo-
philia comprehensive treatment center (HCTC),   including 
hematologists, laboratory staff, nurses, physiotherapists and 
social workers, should involve the collaboration of several 
specialists. Genetic counseling for patients and their families, Journal of Blood Medicine  2010:1 submit your manuscript | www.dovepress.com
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and advice about prenatal diagnosis and management of 
pregnancy and delivery in hemophilia carriers should be 
offered. Joint disease is now minimal in younger patients on 
primary or early secondary prophylaxis, but the impact on 
adult patients is still significant, and likely to increase as the 
life expectancy of hemophilic patients continues to increase. 
Thus, a trained orthopedic surgery team should be available, 
at least at major HCTCs. Another crucial issue for patients 
born before the mid-1980s is the management of chronic 
hepatitis B and C infection and the related long-term com-
plications, and of human immunodeficiency virus infection, 
in particular after the advent of highly active anti-retroviral 
therapy. This requires close interaction with hepatologists 
and infectious disease specialists. Moreover, new challenges 
are emerging in the care of aging patients, not only in terms 
of the comorbidities typically associated with hemophilia, 
but also with regard to common age-related illnesses, such 
as cardiovascular disease and cancer.91
The delivery of a high-quality comprehensive service 
to patients with bleeding disorders has been modeled upon 
defined standards and a network of designated HCTCs in the 
UK, US, and other Western countries.89,92 These principles 
have been summarized recently by the European Association 
for Haemophilia and Associated Disorders.92 In developing 
countries, despite a shortage or absence of treatment prod-
ucts, the development of local expertise thanks to twinning 
programs is resulting in an improved outlook and reduction 
in mortality.89,90 Interestingly, this finding is also true for 
developed countries; in the US, patients who received their 
care in HCTCs had lower hospital admission and mortality 
rates than those who accessed their care outside.93 These data 
highlight the importance of ongoing specialist services for 
this group of patients.
Conclusion and perspectives
Since the advent of modern replacement treatment in the 
early 1970s, hemophilia has become an example of successful 
management of a congenital chronic disease. This has been 
associated with an impressive increase in patient life expec-
tancy, which was previously less than 30 years. In parallel, 
the increasing implementation of prophylaxis in children has 
enabled avoidance of or significant reduction in the crippling 
consequences of hemophilic arthropathy. The development of 
effective viral inactivation techniques, together with methods 
used to screen viruses in blood donations and plasma pools, 
has greatly improved the safety of plasma-derived products, 
confirmed by the fact that no blood-borne transmission of 
hepatitis viruses or human immunodeficiency virus has 
occurred in the last 15 years.5 However, the introduction of 
recombinant products has contributed greatly to the perceived 
increased safety of replacement therapy, and to the more 
widespread use of prophylaxis and home treatment. Because 
of uncertainties with regard to as yet unknown pathogens 
and the potential impact of prion disease in the hemophilic 
population reliant on blood derivatives,94 there has been a 
strong push in some Western countries to treat hemophilic 
children only with rFVIII products, as recommended by 
several national guidelines.2,95 Furthermore, with safety as 
a priority, the manufacturing process for rFVIII products 
has further evolved during the last few years to minimize 
the risk of pathogen transmission, with the improvement of 
protein purification techniques and viral inactivation steps, 
and avoidance of human or animal proteins at any stage of 
their manufacture.96
Prophylactic therapy beginning at an early age should 
be considered the evidence-based treatment of choice for 
children with severe hemophilia, enabling normal physical, 
psychologic, and social development. The optimal regimen 
is still debated. From an analysis of data in the recent litera-
ture it is clear that the intensity and duration of prophylaxis 
should be individualized on the basis of the patient’s clinical 
needs, particularly with respect to venous access. Recent 
studies also suggest a role for delayed secondary prophylaxis 
in increasing joint protection compared with on-demand 
therapy. An undoubtedly favorable impact of prophylaxis is 
detectable at any age. In this respect, the individualization of 
regimens may help to devise more cost-effective treatments. 
It is noteworthy that assessment of outcome in hemophilia 
requires longer follow-up, should not be confined to direct 
costs of concentrates, and should take into account all the 
additional health resources related to the management of 
hemophilia and its orthopedic complications.97 Moreover, 
newer outcome measures useful in determining the overall 
benefits to patients should be added to the clinical outcomes, 
including Health Related Quality of Life (HRQoL) assess-
ment.97 Generic and validated disease-specific HRQoL ques-
tionnaires help to assess and quantify the multidimensional 
perception of well-being, including physical and psychologic 
components.98
The universal implementation of primary prophylaxis 
in children remains impractical, particularly in developing 
countries where only resources for minimal on-demand treat-
ment are available. However, a series of barriers still needs 
to be overcome even in Western countries, including venous 
access, long-term adherence to treatment, and psychosocial 
problems.Journal of Blood Medicine  2010:1 submit your manuscript | www.dovepress.com
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The development of inhibitors is presently the most seri-
ous complication of factor concentrate replacement therapy. 
Although it is the result of a complex interaction between 
multiple genetic and environmental factors, the exact impact 
of single factors, in particular the type of concentrate, 
remains to be established. Recent studies have suggested 
that prophylaxis could exert a protective effect on inhibitor 
risk. A 60%–80% reduction of inhibitor development could 
be expected according to the available data. This possibility 
will have striking implications from the clinical and phar-
macoeconomic points of view in terms of cost-effectiveness 
of prophylaxis and reduction in the highest burden of costs 
for management of patients with inhibitors.
The excellent results in patients without inhibitors are 
leading to prophylaxis approaches using both bypassing 
agents (rFVIIa and APCC) in children with an inhibitor 
because these patients are at high risk of developing severe 
musculoskeletal impairment and life-threatening bleeds. 
However, larger and more rigorous studies are needed to 
confirm that extrapolations from patients without inhibitors 
are applicable to those with inhibitors. Despite uncertainties 
concerning optimal treatment regimens, ITI should be the 
treatment of choice for children with an inhibitor, starting 
when the inhibitor titer is low and with the availability of 
stable and long-lasting venous access.
Hemophilia A and B have been extensively researched in 
the field of gene therapy because they represent monogenic 
disorders for which animal models are available, the threshold 
for success is relatively low (even gene expression at low levels 
of 2%–5% may result in significant modification of clinical 
phenotype), and the outcome may be easily evaluated by 
measuring plasma factor levels. Between 1998 and 2001, five 
Phase I clinical trials were carried out using in vivo gene trans-
fer by different gene delivery systems (  retroviral,   adenoviral, or 
adeno-associated viral vectors as well as nonviral methods).99 
These studies provided important safety data for the various 
strategies used. However, at variance with animal studies, none 
of them achieved long-term expression of the clotting factor at 
therapeutic levels. Human-specific   challenges to gene transfer 
have been shown, particulary related to the immune response 
either against the vector or against the transgene product. 
Therefore, taking a step backwards to animal and cellular 
models, research is now aimed at finding new strategies for 
improving transduction efficacy, identifying the best target 
tissue (liver or muscle), and achieving long-term expression 
in the absence of an immune response.99
In conclusion, although a cure through gene therapy is far 
from being implemented, hemophilia is currently the most 
effectively and safely treated monogenic inherited disorder.5 
However, this statement applies only to patients living in 
Europe, the US, and in a few high-income Asian countries, 
where highly safe antihemophilic products are widely avail-
able and comprehensive care is provided. The main goal for 
the future is to address the lack of satisfactory hemophilia 
care worldwide for more than two-thirds of people with 
hemophilia. Unfortunately, the evolution and increasing avail-
ability of products have not been matched by a decrease in 
their costs. Further encouraging perspectives come from new 
factor concentrates with longer half-lives or other modifica-
tions presently in clinical trials100 or in development99 (Table 
6). These genetically engineered products will enable us 
to reduce the impact of some crucial unsolved issues, like 
the need for frequent infusions and for CVADs in children, 
facilitating the implementation of prophylaxis or ITI, the 
development of inhibitors and, probably, the consumption 
of replacement factors and costs of treatment.
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